4834 Pyrimethamine One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. 58-14-0 4993 C12H13ClN4 White powder. 233.5°C 121 mg/L Well absorbed with peak levels occurring between 2 to 6 hours following administration Pyrimethamine inhibits the dihydrofolate reductase of plasmodia and thereby blocks the biosynthesis of purines and pyrimidines, which are essential for DNA synthesis and cell multiplication. This leads to failure of nuclear division at the time of schizont formation in erythrocytes and liver. Hepatic Half Life: 96 hours 3, not classifiable as to its carcinogenicity to humans. (L135) For the treatment of toxoplasmosis and acute malaria; For the prevention of malaria in areas non-resistant to pyrimethamine 2014-09-11T05:16:14Z 2026-05-14T16:24:39Z Pyrimethamine C07391 8673 DB00205 CP6 true CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1 C12H13ClN4 InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17) WKSAUQYGYAYLPV-UHFFFAOYSA-N 248.711 248.082874143 Exogenous Solid 2.69 HMDB14350 CHEMBL36 4819 <p><a href="http://www.drugsyn.org/Pyrimethamine.htm">DrugSyn.org</a></p> CHEM003736 DTXSID9021217 NS00001824 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine 77.82 71.54200000000002 25.794130782433673 2 4 2 17.222043955485603 7.773183579634736 1 2 2.62 -3.14 1.79e-01 g/l